智通财经网·2026-02-26 11:01Core Viewpoint - The company reported a significant improvement in financial performance for the fiscal year 2025, achieving a total revenue of approximately 1.068 billion yuan, marking a year-on-year growth of 26.18%, and successfully turning a profit with a net profit of approximately 27.87 million yuan, compared to a loss in the previous year [1] Financial Performance - Total revenue for the period reached approximately 1.068 billion yuan, reflecting a year-on-year increase of 26.18% [1] - The net profit attributable to the parent company was approximately 27.87 million yuan, indicating a turnaround from a loss in the previous year [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization, with a focus on the growth of its first quadrivalent meningococcal vaccine, Manhaixin® [1] - Cost reduction and efficiency improvement measures have been effectively executed, leading to better expense management [1] Operational Efficiency - The company has optimized production and sales coordination, resulting in an improvement in gross profit margin [1] - Overall profitability has significantly increased, with the company successfully achieving a positive net profit for the reporting period [1]